Dianthus Therapeutics, Inc.
General ticker "DNTH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.9B (TTM average)
Dianthus Therapeutics, Inc. follows the US Stock Market performance with the rate: 50.0%.
Estimated limits based on current volatility of 2.1%: low 104.95$, high 109.48$
Factors to consider:
- Total employees count: 92 (+17.9%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, No approved products, Need substantial capital, Regulatory and compliance, Clinical trial failure
- Current price 90.2% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [24.37$, 55.08$]
- 2026-12-31 to 2027-12-31 estimated range: [16.33$, 39.42$]
Financial Metrics affecting the DNTH estimates:
- Negative: with PPE of -10.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 92.93 > 81.92
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -7.71 <= -7.11
- Negative: 0 < Industry inventory ratio change (median), % of 0
Short-term DNTH quotes
Long-term DNTH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.83MM | $6.24MM | $2.04MM |
| Operating Expenses | $51.00MM | $108.10MM | $179.97MM |
| Operating Income | $-48.17MM | $-101.86MM | $-177.93MM |
| Non-Operating Income | $4.62MM | $16.89MM | $15.60MM |
| R&D Expense | $32.84MM | $83.11MM | $145.64MM |
| Income(Loss) | $-43.55MM | $-84.97MM | $-162.34MM |
| Net Income(Loss)* | $-43.55MM | $-84.97MM | $-162.34MM |
| Stockholders Equity | $168.87MM | $352.48MM | $493.40MM |
| Assets | $179.41MM | $374.01MM | $530.92MM |
| Operating Cash Flow | $-36.86MM | $-78.18MM | $-129.06MM |
| Capital expenditure | $0.11MM | $0.10MM | $0.21MM |
| Investing Cash Flow | $20.25MM | $-286.81MM | $-122.83MM |
| Financing Cash Flow | $133.57MM | $255.62MM | $280.12MM |
| Earnings Per Share** | $-8.45 | $-2.55 | $-4.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.